Kinexus Bioinformatics Corporation tracks and maps the cell signalling networks of protein kinases for research into the diagnosis, prognosis and treatment of human diseases.
Protein kinases are the key proteins for communication and control inside cells. Their malfunction has been linked to more than 400 human diseases, including cancer, cardiovascular disease, diabetes and inflammation. They are of vital importance in the diagnosis and treatment of diseases.
Currently, Kinexus maps the presence and activation states of over 650 different protein kinases and other signalling proteins and their phospho-sites in cell and tissue specimens through our cell culture, protein microarray, multi-immunoblotting and immunohistochemistry services.
Protein kinases are the key proteins for communication and control inside cells. Their malfunction has been linked to more than 400 human diseases, including cancer, cardiovascular disease, diabetes and inflammation. They are of vital importance in the diagnosis and treatment of diseases.
Currently, Kinexus maps the presence and activation states of over 650 different protein kinases and other signalling proteins and their phospho-sites in cell and tissue specimens through our cell culture, protein microarray, multi-immunoblotting and immunohistochemistry services.
These innovative proprietary services utilize unique and stringent screening methods to facilitate the discovery and validation of drug targets and the rapid exclusion of inappropriate drug leads in the early stages of the drug discovery process. This is further augmented by a complementary suite of on-line bioinformatics services that are offered by Kinexus.
Our unique business model permits the growth of Kinexus through revenues from provision of our unique services, access to thousands of experimental animal and human specimens, and the development of working relationships with thousands of researchers. Over the last 10 years, Kinexus has provided our unique services to over 1300 laboratories in 33 countries.
Our unique business model permits the growth of Kinexus through revenues from provision of our unique services, access to thousands of experimental animal and human specimens, and the development of working relationships with thousands of researchers. Over the last 10 years, Kinexus has provided our unique services to over 1300 laboratories in 33 countries.